

METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours

João Glasberg^{1,2}, Aley Talans^{3,4}, Thomás Rivelli Giollo¹, Débora Zachello Recchimuzzi¹, João Evangelista Bezerra Neto¹, Rossana Veronica Mendonza Lopez⁵, Paulo Marcelo Gehm Hoff¹ and Rachel P Riechelmann^{2,6}

ecancer 16 1369 (2022) <https://doi.org/10.3332/ecancer.2022.1369>

¹Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo – FMUSP, São Paulo, Brazil

²Post Graduate Program, Faculdade de Medicina da Universidade de São Paulo, Brazil

³Department of Medical Radiology, Fleury Group, São Paulo, Brazil

⁴Department of Medical Radiology, Hospital Israelita Albert Einstein, São Paulo, Brazil

⁵Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo – FMUSP, São Paulo, Brazil

⁶Department of Clinical Oncology, AC Camargo Cancer Center, São Paulo, Brazil

Keywords: *neuroendocrine tumours, metformin, cancer treatment*

Thomás Rivelli Giollo is corrected to Thomás Giollo Rivelli

Correspondence to: Rachel P Riechelmann
Email: rachel.riechelmann@accamargo.org.br

ecancer 2022, 16:1421
<https://doi.org/10.3332/ecancer.2022.1421>

Published: 04/07/2022

Received: 14/06/2022

Publication costs for this article were supported by ecancer (UK Charity number 1176307).

Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.